Cost-effectiveness analysis of antiemetics therapy in breast cancer patients with moderate emetogenic chemotherapy in Prof. Dr. Margono Soekarjo Hospital, Indonesia

Authors

  • Ida Dzikriyani
  • Didik Setiawan Fakultas Farmasi, Universitas Muhammadiyah Purwokerto

DOI:

https://doi.org/10.12928/pharmaciana.v11i3.17650

Keywords:

Cost effectiveness analysis, breast cancer, ondansetron, dexamethasone, ranitidine

Abstract

Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several antiemetic combinations in breast cancer patients in Prof. Dr. Margono Soekardjo Hospital, Purwokerto, Indonesia was the aim of this research. Seventy-four Breast cancer patients who have prescribed moderate-emetogenic chemotherapy during the year 2017-1019 were included in this research. There were fifteen patients treated with the combination of ondansetron and dexamethasone (OD). Fourteen patients were treated with the combination of ondansetron and ranitidine (OR). Thirty-five patients were treated using ondansetron, dexamethasone, and ranitidine (ODR) combination. The effectiveness was represented by the absence of acute nausea and vomiting after receiving chemotherapy. The ODR combinations showed the highest effectivity on diminishing nausea and vomiting among breast cancer patients (0.400), followed by the OD combination (0.267) and the OR combination (0.214). However, the ODR combination generates the highest cost (4.6 million rupiahs) compared to other antiemetics combinations. Compared to the combination of ondansetron and dexamethasone, the combination of ODR provides higher ICER (ICER of 13 Million Rupiahs per case prevented) than the combination of OR (ICER of 8.5 million Rupiahs per case prevented). In conclusion, the combination of ondansetron, dexamethasone, and ranitidine generates the highest cost. It also provides the highest effectiveness in preventing nausea and vomiting.

Author Biography

Didik Setiawan, Fakultas Farmasi, Universitas Muhammadiyah Purwokerto

H index Scopus: 2

Scopus ID: 256543713300

https://scholar.google.co.id/citations?user=jPV689gAAAAJ&hl=id&oi=ao

References

Assessment, I. H. T. (2017). Health Technology Assessment (HTA) Guideline.

Belhekar, M. N., Taur, S. R., & Munshi, R. P. (2014). A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian Journal of Pharmacology, 46(1), 117–120. https://doi.org/10.4103/0253-7613.125192

Diaby, V., Tawk, R., Sanogo, V., Xiao, H., & Montero, A. J. (2015). A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Research and Treatment, 151(1), 27–40. https://doi.org/10.1007/s10549-015-3383-6

Diener, K. M. (1998). Chemotherapy-induced nausea and vomiting. Journal of Pharmaceutical Care in Pain & Symptom Control, 6(4), 23–50. https://doi.org/10.1300/J088v06n04_03

Engstrom, C., Hernandez, I., Haywood, J., & Lilenbaum, R. (1999). The efficacy and cost effectiveness of new antiemetic guidelines. Oncology Nursing Forum, 26((9)), 1453–1458

García-Cortés, M., Lucena, M. I., Pachkoria, K., Borraz, Y., Hidalgo, R., & Andrade, R. J. (2008). Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Alimentary Pharmacology & Therapeutics, 27(9), 780–789. https://doi.org/10.1111/j.1365-2036.2008.03655.x

Greimel, E. R., Winter, R., Kapp, K. S., & Haas, J. (2009). Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology, 18 (5), 476-482

Hesketh, P. J. (2008). Chemotherapy-induced nausea and vomiting. New England Journal of Medicine, 358(23), 2482–2494. https://doi.org/10.1056/NEJMra0706547

Indonesia, M. K. R. (2013). Standar tarif pelayanan kesehatan pada fasilitas kesehatan tingkat pertama dan fasilitas kesehatan tingkat lanjutan dalam penyelenggarakan program jaminan kesehatan

J, Ferlay., M, Ervik., F, Lam., M, Colombet., L, Mery., M, Piñeros., A, Znaor., & B, Soerjomataram. I. (2018). Cancer Today (powered by Globocan 2018)

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90. https://doi.org/10.3322/caac.20107

Kang, H. J., Loftus, S., DiCristina, C., Green, S., Pong, A., & Zwaan, C. M. (2018). Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. Pediatric Blood & Cancer, 65(10), e27273. https://doi.org/10.1002/pbc.27273

Muñoz, M., & Coveñas, R. (2019). Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. Anti-Cancer Agents in Medicinal Chemistry, 19(1), 92–100. https://doi.org/10.2174/1871520618666180420165401

Navari, R. M. (2015). 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1848(10), 2738–2746. https://doi.org/10.1016/j.bbamem.2015.03.020

Navari, R. M., & Aapro, M. (2016). Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New England Journal of Medicine, 374(14), 1356–1367. https://doi.org/10.1056/NEJMra1515442

Perez, E. A. (1998). Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting. The Cancer Journal from Scientific American, 4(2), 72–77

Pradermdee, P., Manusirivithaya, S., Tangjitgamol, S., Thavaramara, T., & Sukwattana, P. (2006). Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 89 Suppl 4, S29-36

Schädlich, P. K., Klussmann, Chen, & Rémy. (2013). Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. ClinicoEconomics and Outcomes Research, 203. https://doi.org/10.2147/CEOR.S43393

Setiawan, D., Dolk, F. C., Suwantika, A. A., Westra, T. A., WIlschut, J. C., & Postma, M. J. (2016). Cost-utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia. Value in Health Regional Issues, 9, 84–92. https://doi.org/10.1016/j.vhri.2015.10.010

Shankar, A., Roy, S., Malik, A., Julka, P., & Rath, G. (2015). Prevention of chemotherapy-induced nausea and vomiting in cancer patients. Asian Pacific Journal of Cancer Prevention, 16(15), 6207–6213. https://doi.org/10.7314/APJCP.2015.16.15.6207

Downloads

Published

2021-10-23

Issue

Vol. 11 No. 3 (2021): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.